临床药师参与1例药源性重度血小板减少症的病例分析

目的 探讨急性心肌梗死患者经皮冠脉介入治疗术（PCI）后发生严重药源性血小板减少症（DITP）的相关药物。方法 临床药师对该例患者的用药情况进行分析，协助制定药源性血小板减少症的对症治疗方案并全程实施药学监护。结果 临床药师判定替罗非班为致血小板减少症的可疑药物。经对症治疗后，患者血小板逐渐恢复正常，病情缓解出院。结论 临床药师参与药源性血小板减少症患者的治疗与监护，可减少不良反应的发生，保障患者的用药安全。

Medication analysis of clinical pharmacists participating in one patient with severe drug-induced thrombocytopenia

Objective To investigate the related drugs of severe drug-induced thrombocytopenia in patients with acute myocardial infarction after percutaneous coronary intervention (PCI).Methods The typical cases participated by clinical pharmacist were shared and analyzed from three aspects of analyzation of drugs that may caused drug-induced thrombocytopenia, formulation of therapeutic regimen and implementation of pharmaceutical care.Results Tirofiban as a suspect drug for thrombocytopenia was identified. Platelets of the patient gradually returned to normal level with symptomatic treatment.The patient discharged after symptomatic remission.Conclusion Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia,can reduce the occurrence of adverse reactions,to ensure the safety of patients.